We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual...
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
TPST-1120, a first-in-class, oral, selective PPARβΊ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized...
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in...
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2512 | -7.09604519774 | 3.54 | 3.5839 | 3.12 | 369654 | 3.3113193 | CS |
4 | 0.1288 | 4.07594936709 | 3.16 | 3.79 | 3.0611 | 351018 | 3.42893619 | CS |
12 | -0.4212 | -11.3530997305 | 3.71 | 6 | 3.03 | 896391 | 4.34776121 | CS |
26 | 0.0288 | 0.883435582822 | 3.26 | 6 | 2.88 | 1010818 | 4.12376266 | CS |
52 | 1.1988 | 57.3588516746 | 2.09 | 9.77 | 0.17 | 3150111 | 5.85755695 | CS |
156 | -10.5212 | -76.1853729182 | 13.81 | 41 | 0.17 | 1203318 | 6.38743068 | CS |
260 | -10.5212 | -76.1853729182 | 13.81 | 41 | 0.17 | 1203318 | 6.38743068 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions